Membranous nephropathy (MN) resulting in nephrotic syndrome is a rare and late event after allogeneic haematopoietic SCT with minimal follow-up data currently available. Combined treatment with immunosuppressants and corticosteroids remains the mainstay of treatment of this complication, usually associated with chronic GVHD. Most recently, preliminary data have suggested that rituximab may prove helpful as a targeted salvage treatment in this specific clinical setting. We report successful salvage treatment with rituximab in an adult HSCT recipient suffering from extensive chronic GVHD associated with MN and invasive aspergillosis. In March 2006, a 60-year-old white male patient with a past medical history significant for stage IIIA k light chain multiple myeloma (MM), diagnosed in November 2003, presented with weight gain and peripheral edema. He had undergone autologous-allogeneic tandem HSCT in January and April 2004, after conditioning with melphalan (200 mg/m 2 ) and 2 Gy TBI, respectively, according to the original Seattle regimen. 1 The source of allogeneic PBPC was an human leukocyte Ag-identical sibling donor. GVHD prophylaxis consisted of mycophenolate mofetil (MMF) and cyclosporine (CSP). Sustained long-term engraftment was observed. He had grade I acute GVHD and later presented with extensive chronic GVHD, treated with CSP and corticosteroids. Tumor response occurred slowly and treatment with thalidomide was begun in November 2005. Re-staging investigations ruled out MM relapse. Laboratory values were remarkable for hypoalbuminemia (2.7 g/ dl), proteinuria (2.1 g/24 h) and a decreased creatinine clearance (71 mg/min). Hepatitis B and C, autoimmune, and human immunodeficiency virus serologies were negative. Two months later, proteinuria had increased to a nephrotic level of 3.6 g/24 h and a serum creatinine level of 1.3 mg/dl was observed. He underwent a percutaneous renal biopsy, which disclosed features of stage II MN by light microscopy (interstitial fibrosis and arteriolar hyaline thickening) and immunofluorescent study (IgG, C3 and C1q deposits). Combined therapy with the angiotensinconverting enzyme inhibitor (ACEi) lisinopril, CSP and prednisolone failed to reduce proteinuria. Despite administration of the statin atorvastatin, anti-coagulant treatment, switch to ramipril and retreatment with MMF, proteinuria significantly increased, up to 6.7 g/24 h after 8 months of therapy ( Figure 1 ). In December 2006, he presented with active manifestations of extensive chronic GVHD, anorexia, nausea, diarrhea and abdominal pain. Lower endoscopy was performed and multiple biopsies were taken from the rectosigmoid colon with histopathological evidence of intestinal GVHD. Investigations revealed heavy proteinuria (26.8 g/24 h), a creatinine level of 2.5 mg/dl, a total serum protein of 4.4 g/dl and a serum albumin of 2.1 g/dl. Immunofixation ruled out monoclonal free light chains in the serum or urine. MMF administration was discontinued and CSP was reinitiated; specialized nutritional support, diuretics and albumin infusions were administered. After supportive therapy and CSP reinitiation, an initial significant reduction of proteinuria was observed, followed a few weeks later by a new increase in urinary protein excretion up to 9.8 g/24 h ( Figure 1 ). Further deterioration of renal function occurred and CSP was discontinued. Therefore, in February 2007, treatment with rituximab (375 mg/m 2 ) for four doses was started. Rituximab was given at irregular intervals due to his poor performance status and to the development of invasive pulmonary aspergillosis treated with voriconazole. The last rituximab infusion was administered in April 2007. Treatment was well tolerated without adverse reactions or side effects. Progressive improvement in GVHD symptoms and reduction in proteinuria occurred. Two months after the last infusion of rituximab, the urinary protein excretion rate decreased to o1 g/24 h; thereafter, a persistent PR, defined as a proteinuria of 0.2 to 2 g/day, was observed ( Figure 1 ). 2 MMF administration was then reinitiated, and, at the last follow-up, 24 months after rituximab treatment, he is free of edema, serum albumin is within normal limits, creatinine is slightly increased (1.4 mg/dl) and proteinuria is 0.7 g/24 h.
The entity of renal GVHD, specified as glomerular lesions resulting in nephrotic syndrome, was recently identified as an under-reported, late complication of both conventional and reduced-intensity or non-myeloablative allogeneic HSCT, usually associated with active manifestations of chronic GVHD and modification of immunosuppression. [3] [4] [5] [6] Among the variable glomerular histologies described in this unique clinical setting, comprising mainly MN and less frequently minimal change disease or other renal diseases, MN occurred later and exhibited a worse prognosis in comparison with other histology findings. [3] [4] [5] Combined treatment with immunosuppressive agents and corticosteroids remains the mainstay of initial treatment of MN in allogeneic HSCT recipients. 3 Most recently, preliminary data have suggested that the anti-CD20 chimeric MoAb, rituximab, may prove helpful as a salvage treatment in patients with MN after allogeneic HSCT. 4, 6 These results are in keeping with the observation that rituximab is an effective therapeutic option for extensive steroid-refractory chronic GVHD. 7, 8 In contrast, other case series failed to show any role for rituximab in ameliorating MN associated with chronic GVHD. 5, 9 However, the seemingly good prognosis of post-allogeneic HSCT MN treated with rituximab has to be weighed against the lack of long-term outcome data, as the longest available follow-up was only 7 months. 6 This case is interesting owing to medical comorbidities and therapeutic problems, in that deterioration of renal function and the increased risk of spreading life-threatening fungal infection contraindicated further immunosuppressive or myelosuppressive treatments. Rituximab treatment was highly effective resulting in a persistent PR in the long term. However, we cannot exclude a beneficial effect of combined concomitant ACEi and corticosteroid therapy for proteinuria. Toxicity of this treatment was negligible. The temporal association between active symptoms of chronic GVHD and nephrotic syndrome development, and their concomitant improvement after rituximab treatment seems to confirm the existence of renal feature of chronic GVHD in our case. Although we do not have direct data on the clearance of peripheral blood B cells, we suppose on clinical grounds that rituximab efficacy in the secondary immunosuppression for MN might be related to its action on the B-cell component of chronic GVHD. In conclusion, this report points to the efficacy of rituximab as a salvage treatment for chronic GVHD with renal involvement and to its favourable riskbenefit profile. However, evidence of long-term benefit from rituximab treatment in this specific clinical setting is still lacking. 
